3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Melanoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Thyroid Gland Carcinoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Lobular
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
lutetium Lu 177 dotatate
15
Everolimus
11
Nivolumab
10
pembrolizumab
9
Temozolomide
9
Capecitabine
7
cabozantinib
6
Sunitinib
6
lenvatinib
5
lanreotide
4
gallium Ga 68 dotatate
4
Ipilimumab
4
Etoposide
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
telotristat ethyl
3
pazopanib
3
avelumab
3
Octreotide
3
Magnetic Resonance Spectroscopy
3
Injections
3
Cyclophosphamide
3
Cisplatin
3
Bevacizumab
3
surufatinib
2
sintilimab
2
fosbretabulin
2
fludarabine
2
Specimen Handling
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroendocrine Tumors
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA